SLS News and Press, SELLAS Life Sciences Group Inc.

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE ...

2026-03-05 12:01:40 ET Investment Overview New York headquartered Sellas Life Sciences ( SLS ) listed on the Nasdaq in August 2017 via a merger with struggling biotech Galena Biopharma - a press release at the time stated: SELLAS’ lead asset, galinpepimut-S ...

2026-01-19 08:07:13 ET Sellas Life Sciences’ stock ( SLS ) has risen >300% in the past year ahead of Phase 3 data for its peptide immunotherapy, galinpepimut-S (GPS), in patients with AML in second remission.... Read the full article on Seeking Alpha For furthe...

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment  U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramb...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 9.2% to $2.3963 on volume of 453,152,238 shares Envirotech Vehicles Inc. (EVTV) rose 55.6% to $0.6 on volume of 374,606,573 shares Oriental Culture Holding LTD (OCG) fell 41.5% to ...

2026-01-02 15:00:31 ET More on the markets Realistic Expectations For 2026 Market Rotation Alert: Positioning For A Potentially Tumultuous Year S&P 500 And Bitcoin: After 4 Years Of Mediocrity From The Latter, I Own Both, Here's Why Steady start to 2026: ...

2025-12-30 14:10:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks. After dropping to a low of 3,637.05 in October 2023, the ...

Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomes Timing of the final analysis is event-driven, and SELLAS will announce the occurrence of the 80 th event...

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034 [1] , driven by a fundamental shift in how physicians combat cancer's most resistant forms. ...